Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justus Duyster

Showing results (1-10 of 248) with videos related to

Pageof 25
Sort By:
Oncology Research and Treatment|March 22, 2018
Anti-Angiogenics: Current Situation and Future PerspectivesKatja Zirlik, Justus Duyster
Deutsches Arzteblatt International|March 12, 2010
Chronic myelogenous leukemia: treatment and monitoringNikolas von Bubnoff, Justus Duyster
Cell Cycle (Georgetown, Tex.)|November 1, 2005
Mitotic entry: a matter of oscillating destructionFlorian Bassermann, Christian Peschel, Justus Duyster
Current Drug Targets|November 1, 2006
Targeting the oncogenic tyrosine kinase NPM-ALK in lymphoma: the role of murine models in defining pathogenesis and treatment optionsCornelius Miething, Christian Peschel, Justus Duyster
Plos One|May 23, 2014
Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutationsChuanjiang Yu, Rama Krishna Kancha, Justus Duyster
Plos One|July 12, 2013
Analysis of conformational determinants underlying HSP90-kinase interactionRama Krishna Kancha, Natalie Bartosch, Justus Duyster
Cancers|September 21, 2018
Current Immunotherapeutic Approaches in T Cell Non-Hodgkin LymphomasTeresa Poggio, Justus Duyster, Anna L Illert
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2011
The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitorsRama Krishna Kancha, Christian Peschel, Justus Duyster
Blood|June 21, 2007
The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigensFlorian Scheich, Justus Duyster, Christian Peschel, et al.
Cell Communication and Signaling : CCS|June 14, 2013
Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylationRama Krishna Kancha, Nikolas von Bubnoff, Justus Duyster
Pageof 25

Showing results (1-10 of 248) with videos related to

Sort By:
Pageof 25
Oncology Research and Treatment|March 22, 2018
Anti-Angiogenics: Current Situation and Future PerspectivesKatja Zirlik, Justus Duyster
Deutsches Arzteblatt International|March 12, 2010
Chronic myelogenous leukemia: treatment and monitoringNikolas von Bubnoff, Justus Duyster
Cell Cycle (Georgetown, Tex.)|November 1, 2005
Mitotic entry: a matter of oscillating destructionFlorian Bassermann, Christian Peschel, Justus Duyster
Current Drug Targets|November 1, 2006
Targeting the oncogenic tyrosine kinase NPM-ALK in lymphoma: the role of murine models in defining pathogenesis and treatment optionsCornelius Miething, Christian Peschel, Justus Duyster
Plos One|May 23, 2014
Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutationsChuanjiang Yu, Rama Krishna Kancha, Justus Duyster
Plos One|July 12, 2013
Analysis of conformational determinants underlying HSP90-kinase interactionRama Krishna Kancha, Natalie Bartosch, Justus Duyster
Cancers|September 21, 2018
Current Immunotherapeutic Approaches in T Cell Non-Hodgkin LymphomasTeresa Poggio, Justus Duyster, Anna L Illert
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2011
The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitorsRama Krishna Kancha, Christian Peschel, Justus Duyster
Blood|June 21, 2007
The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigensFlorian Scheich, Justus Duyster, Christian Peschel, et al.
Cell Communication and Signaling : CCS|June 14, 2013
Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylationRama Krishna Kancha, Nikolas von Bubnoff, Justus Duyster
Pageof 25